In 2018, to strengthen the management of rare diseases in China, improve the diagnosis and treatment level of rare diseases, and protect the health rights of patients with rare diseases, the National Health Commission and other five departments jointly formulated the "First List of Rare Diseases." Subsequently, on February 25, 2019, the National Health Commission issued the "Notice on Establishing a National Collaborative Network for the Diagnosis and Treatment of Rare Diseases," forming a national collaborative network for the diagnosis and treatment of rare diseases. On February 27, 2019, the National Health Commission released the "Rare Disease Diagnosis and Treatment Guidelines (2019 Edition)." Rare diseases are increasingly receiving attention at the policy level, public awareness is continuously improving, and diagnostic rates are also increasing. At the same time, an increasing number of rare disease drugs have been approved for marketing, with eight rare disease drugs being approved for marketing in China in 2019.
With the continuous improvement and perfection of hemophilia diagnosis and treatment levels and the social security system in China, the treatment needs of hemophilia patients have been upgraded from maintaining life and alleviating pain in the past to expecting a life like healthy people.
PINGAN GOOD DOCTOR, as an important component of Ping An Group's managed care model and the flagship of the medical ecosystem, leverages core competitive advantages such as abundant payer resources, a comprehensive supplier network, a leading service system, and strong ecosystem empowerment to create a unique business model based on managed care + family doctor membership + O2O healthcare services. As of June 30, 2022, PINGAN GOOD DOCTOR had over 440 million cumulative registered users, more than 1.3 billion cumulative consultations, and a team of nearly 49,000 internal and external doctors from 20 departments, along with fitness coaches, nutritionists, and psychological counselors.
China Social Assistance Foundation is one of the first charitable organizations recognized by the Ministry of Civil Affairs with the qualification for public fundraising. Since its establishment in January 2009, the foundation has adhered to the mission of "pooling love and good deeds from home and abroad, promoting traditional Chinese virtues, assisting extremely impoverished groups in urban and rural areas, advancing the development of social assistance, and serving a harmonious and civilized society." Upholding the vision of "ensuring the vulnerable live in peace and empowering the poor to become self-reliant," it has successively carried out various public welfare projects including aiding the weak and needy, educational support, critical illness assistance, and disaster relief. To date, it has raised over 2.3 billion yuan in donations, benefiting millions of people.
With a history of 170 years, Pfizer has been committed to providing therapeutic solutions to people through science and global resources. Throughout the exploration, research, development, and production of healthcare products, Pfizer consistently adheres to strict standards of quality, safety, and value. Pfizer's global portfolio includes innovative medicines and vaccines aimed at advancing human health and promoting the prevention, treatment, and cure of diseases to address various intractable illnesses. Pfizer also collaborates with healthcare providers, governments, and communities to support and enhance access to reliable and affordable healthcare services for people around the world.
This time, the Chinese Social Assistance Foundation, Ping An Healthcare and Technology Company Limited, and Pfizer have reached a strategic cooperation aimed at fully leveraging their respective advantages to address the five major needs of patients: diagnosis, treatment, rehabilitation, efficacy monitoring, and payment solutions. At the same time, the joint participation of various sectors of society—government, enterprises, public welfare organizations, volunteers, and more—will create a favorable environment for hemophilia patients to return to a normal life, supporting their reintegration into society and helping them receive standardized and high-quality diagnosis and treatment close to home.
